EXCELLENT TRANSPLANT OUTCOMES WITH FLUDARABINE-TREOSULFAN (FT) REDUCED-TOXICITY CONDITIONING (RTC) IN COMBINATION WITH DUALT-CELL DEPLETION (TCD) IN MYELOABLATIVE CONDITIONING (MAC)-INELIGIBLE PATIENTS WITH MYELODYSPLASTIC SYNDROME (MDS)

被引：0
|
作者：
Pasic, I. [1 ,2 ]
Remberger, M. [3 ]
Chen, C. [2 ]
Gerbitz, A. [1 ,2 ]
Kim, D. [1 ,2 ]
Kumar, R. [1 ,2 ]
Lam, W. [1 ,2 ]
Law, A. [1 ,2 ]
Lipton, J. [1 ,2 ]
Michelis, F. [1 ,2 ]
Novitzky-Basso, I. [1 ,2 ]
Viswabandya, A. [1 ,2 ]
Mattsson, J. [1 ,2 ]
机构：
[1] Univ Toronto, Med, Toronto, ON, Canada
[2] Princess Margaret Hosp, Canc Ctr, Med Oncol & Hematol, Toronto, ON, Canada
[3] Uppsala Univ Hosp, Med Sci, Uppsala, Sweden
来源：
LEUKEMIA RESEARCH | 2023年 / 128卷
关键词：
D O I：
10.1016/j.leukres.2023.107131
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O18
引用
收藏
页数：1
相关论文
共 10 条
  • [1] Prospective evaluation of oral mucositis in allogeneic stem cell transplant recipients receiving conventional myeloablative conditioning or reduced-toxicity conditioning with treosulfan and fludarabine
    Uotinen, H.
    Volin, L.
    Juvonen, E.
    Nihtinen, A.
    Ruutu, T.
    BONE MARROW TRANSPLANTATION, 2008, 41 : S72 - S72
  • [2] Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS)
    N Kröger
    A Shimoni
    T Zabelina
    H Schieder
    J Panse
    F Ayuk
    C Wolschke
    H Renges
    J Dahlke
    D Atanackovic
    A Nagler
    A Zander
    Bone Marrow Transplantation, 2006, 37 : 339 - 344
  • [3] Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS)
    Kröger, N
    Shimoni, A
    Zabelina, T
    Schieder, H
    Panse, J
    Ayuk, F
    Wolschke, C
    Renges, H
    Dahlke, J
    Atanackovic, D
    Nagler, A
    Zander, A
    BONE MARROW TRANSPLANTATION, 2006, 37 (04) : 339 - 344
  • [4] ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (SCT) USING FLUDARABINE/TREOSULFAN CONDITIONING REGIMEN COMPARED WITH BUSULFAN-BASED MYELOABLATIVE AND REDUCED-INTENSITY CONDITIONING IN PATIENTS WITH AML AND MDS; RELATIVE OUTCOMES DEPEND ON DISEASE STATUS AT SCT
    Shimoni, A.
    Shem-Tov, N.
    Rand, A.
    Volchek, Y.
    Yerushalmi, R.
    Hardan, I
    Nagler, A.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2010, 16 (02) : S231 - S231
  • [5] Allogeneic Hematopoietic Stem-Cell Transplantation Using Fludarabine/Treosulfan Conditioning Regimen Compared with Busulfan-Based Myeloablative and Reduced-Intensity Conditioning in Patients with AML and Mds; Relative Outcomes Depend On Disease Status at Transplantation
    Shimoni, Avichai
    Rand, Avital
    Shem-Tov, Noga
    Hardan, Izhar
    Volchek, Yulia
    Maayaan, Hannah
    Yerushalmi, Ronit
    Nagler, Arnon
    BLOOD, 2009, 114 (22) : 1303 - 1304
  • [6] Allogeneic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome (MDS) Using Treosulfan Based Compared to Standard Reduced-Intensity or Myeloablative Conditioning Regimens. a Report of the Chronic Malignancies Working Party of EBMT
    Shimoni, Avichai
    Robin, Marie
    Iacobelli, Simona
    van Biezen, Anja
    Beelen, Dietrich Wilhelm
    Mufti, Ghulam J.
    Ciceri, Fabio
    Kanz, Lothar
    Volin, Liisa
    Blaise, Didier
    Ganser, Arnold
    Luft, Thomas
    Chevallier, Patrice
    Schwerdtfeger, Rainer
    de Witte, Theo
    Kroger, Nicolaus
    Nagler, Arnon
    Yakoub-Agha, Ibrahim
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S35 - S35
  • [7] Myeloablative Reduced-Toxicity i.v. Busulfan-Fludarabine and Allogeneic Hematopoietic Stem Cell Transplant for Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome in the Sixth through Eighth Decades of Life
    Alatrash, Gheath
    de Lima, Marcos
    Hamerschlak, Nelson
    Pelosini, Matteo
    Wang, Xuemei
    Xiao, Lianchun
    Kerbauy, Fabio
    Chiattone, Alexandre
    Rondon, Gabriela
    Qazilbash, Muzaffar H.
    Giralt, Sergio A.
    Silva, Leandro de Padua
    Hosing, Chitra
    Kebriaei, Partow
    Zhang, Weiqing
    Nieto, Yago
    Saliba, Rima M.
    Champlin, Richard E.
    Andersson, Borje S.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2011, 17 (10) : 1490 - 1496
  • [8] ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) FOR PATIENTS IN THE 6TH AND 7TH DECADES OF LIFE WITH AML OR MDS USING MYELOABLATIVE, REDUCED TOXICITY IV BUSULFAN/FLUDARABINE (BUFLU) CONDITIONING REGIMEN
    Alatrash, G.
    Andersson, B.
    Pelosini, M.
    Rondon, G.
    Qazilbash, M.
    Giralt, S.
    Silva, L. de Padua
    Hosing, C.
    Kebriaei, P.
    Zhang, W.
    Saliba, R.
    Champlin, R.
    de Lima, M.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2009, 15 (02) : 106 - 106
  • [9] The efficacy and safety of a new reduced-toxicity conditioning with 4 days of once-daily 100mg/m2 intravenous busulfan associated with fludarabine and antithymocyte globulins prior to allogeneic stem cell transplantation in patients with high-risk myelodysplastic syndrome or acute leukemia
    Wanquet, Anne
    Crocchiolo, Roberto
    Furst, Sabine
    Granata, Angela
    Faucher, Catherine
    Devillier, Raynier
    Harbi, Samia
    Lemarie, Claude
    Calmels, Boris
    Vey, Norbert
    Weiller, Pierre Jean
    Chabannon, Christian
    Castagna, Luca
    Blaise, Didier
    El-Cheikh, Jean
    LEUKEMIA & LYMPHOMA, 2016, 57 (10) : 2315 - 2320
  • [10] An observational audit to evaluate the relation between transfusions and iron toxicity on major outcome parameters in patients with adult myelodysplastic syndrome or chronic myelomonocytic leukaemia treated with myeloablative conditioning and reduced-intensity conditioning allogeneic haematopoietic stem cell transplantation without prior intensive antileukaemic therapy; a non-interventional prospective study by the MDS subcommittee of the Chronic Leukaemia Working Party of the EBMT
    de Witte, T.
    van Biezen, A.
    Spinnewijn, L.
    Scholten, M.
    Maertens, J.
    Socie, G.
    Beelen, D. W.
    Niederwieser, D.
    Kobbe, G.
    Nagler, A.
    Finke, J.
    Kroeger, N.
    BONE MARROW TRANSPLANTATION, 2011, 46 : S32 - S32
1